beta thalassemia major. Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia major
Conditions
Interventions
Intervention 1: Intervention group: a group of 42 thalassemia patients recieved quercetin tablets.They consumed one tablet containing 500 mg quercetin after lunch every day for 3 months and they were
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 18 to 40 year old male and female beta thalassemia major patients Inclination to cooperate and signing the written informed consent A minimum of 2 years of blood transfusion history blood specimen collection 20 days after the last blood transfusion Regular and peculiar iron-chelating therapy with desferrioxamine Vitamin C supplement intake with desferrioxamine
Exclusion criteria
Exclusion criteria: Uncontrollable and life threatening complication due to due to the supplement intake;; ; ; ; ; ; A change in type or amount of the iron chelator Pregnancy or lactation Hepatitis infection and other metabolic or infectious diseases Less than 80% compliance of supplement intake Consumption of drugs that interfere with quercetin Drinking more than 500 mg/day of beverages rich in flavonoids Smoking or alcohol consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: before and after the intervention. Method of measurement: Beck's questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| High-sensitivity C-reactive protein(hs-CRP). Timepoint: before and after the intervention. Method of measurement: using ELISA kit in Microgram/milliliter(micg/ml).;Tumor necrosis factor a(TNF-a). Timepoint: before and after the intervention. Method of measurement: using ELISA kit in Picrogram/milliliter(pg/ml). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Azita Azarkeivan
Blood Transfusion Education & Research Institute.
Outcome results
None listed